Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries. These products are manufactured to cGMP standards, and in both product areas the company has distinguished itself for:
Global regulatory compliance
Consistent high quality
Extensive regulatory documentation
Secure global supply chain
High levels of service and support
Best-quality recombinant insulin Novo Nordisk Pharmatech has become the leading supplier of insulin for cell culture processes by providing excellence at every step of the supply chain – beginning with the quality of its insulin, which is sourced directly from Novo Nordisk, the world’s largest producer. Its recombinant insulin is a key component in serum free growth media for mammalian cells. It is used for the manufacturing of monoclonal antibodies, virus vaccines, gene therapy products and many other biological drug products approved by regulatory bodies worldwide, including FDA and EMA.